Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Diabetic Neuropathy
Interventions
DRUG

QR-333

QR-333 or placebo will be applied three times a day for 12 weeks

Trial Locations (19)

14209

Kaleida Health, Diabetes Center of WNY, Buffalo

27834

ECU Diabetes Research Center, Brody School of Medicine, Greenville

29621

Hartwell Research Group / Anderson Family Care, Anderson

33401

Metabolic Research Institute, Inc., West Palm Beach

33613

Stedman Clinical Trails, Tampa

34471

Renstar Medical Research, Ocala

35201

Baptist Clinical Research, Pensacola

35215

Parkway Medical Center, Birmingham

35216

Seale Harris Clinic / Alliance Clinical Research, Birmingham

63141

A&A Pain Institute, St Louis

75390

UT Southwestern Medical Center at Dallas, Dallas

78229

dgd Research, San Antonio

Endeavor Clinical Trials, PA, San Antonio

90712

Advanced Medical Research, LLC, Lakewood

92708

Pacific Sleep Medicine Services, Inc, Fountain Valley

94598

Diablo Clinical Research, Inc., Walnut Creek

98057

Rainier Clinical Research Center, Inc, Renton

08903

Rwjms/Umdnj, New Brunswick

07006

Land Clinical Studies, West Caldwell

All Listed Sponsors
lead

Quigley Pharma, Inc.

INDUSTRY

NCT00568035 - Safety and Efficacy Study of QR-333 in Patient's With Symptomatic Diabetic Neuropathy | Biotech Hunter | Biotech Hunter